NEUROONE MEDICAL TECHNOLOGIES Corp

For the period ended Sep 30, 2025. Filed Dec 17, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Dec 17, 2025

NMTC$0.89+0.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets

	As of September 30,
	2025	2024
Assets
Current assets:
Cash and cash equivalents	$6,570,382	$1,460,042
Accounts receivable	1,264,805	176,636
Inventory	2,226,805	2,635,153
Deferred offering costs	22,920	142,633
Prepaid expenses	141,372	216,461
Total current assets	10,226,284	4,630,925
Intangible assets, net	44,946	67,262
Right-of-use asset	255,195	254,910
Property and equipment, net	259,222	416,843
Total assets	$10,785,647	$5,369,940
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$1,010,369	$1,029,206
Accrued expenses and other liabilities	1,292,714	1,184,014
Total current liabilities	2,303,083	2,213,220
Warrant liability	1,266,894	2,140,315
Operating lease liability, long term	143,148	194,392
Total liabilities	3,713,125	4,547,927
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding.	—	—
Common stock, $0.001 par value; 100,000,000 shares authorized; 50,006,464 and 30,816,499 shares issued and outstanding as of September 30, 2025 and 2024, respectively.	50,006	30,816
Additional paid–in capital	85,632,303	75,795,610
Accumulated deficit	(78,609,787)	(75,004,413)
Total stockholders’ equity	7,072,522	822,013
Total liabilities and stockholders’ equity	$10,785,647	$5,369,940

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.